Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Migration of unmigrated content due to installation of a new plugin

This example shows findings from an assessment of the number of mutations within a tumor genome with the purpose of determining likely response to a therapeutic agent and/or disease burden. In this example, findings are generated by two vendors using different methodologies and specimen types.


Dataset wrap
Namegf


Rowcaps


Row 1:

Shows the number of sequence variants within the region of interest. The vendor, methodology, and specimen type are shown in GFNAM, GFMETHOD, and GFSPEC. 

Row 2:

Shows the normalized number of sequence variants within the region of interest

Jira
showSummaryfalse
serverIssue Tracker (JIRA)
serverId85506ce4-3cb3-3d91-85ee-f633aaaf4a45
keyECC-12
. The panel of genes used in next generation targeted sequencing is shown in SPDVID. The vendor, methodology, and specimen type are shown in GFNAM, GFMETHOD, and GFSPEC. 

Row 3:Shows the a summary of the magnitude of the variant burden within the tumor. The panel of genes used in next generation targeted sequencing is shown in SPDVID. The vendor, methodology, and specimen type are shown in GFNAM, GFMETHOD, and GFSPEC. 



Dataset2


RowSTUDYIDDOMAINUSUBJIDSPDEVIDGFSEQGFREFIDGFTESTCDGFTESTGFTSTDTLGFORRESGFORRESUGFSTRESCGFSTRESNGFSTRESUGFGENREFGFNAMGFSPECGFMETHODVISITNUMVISITVISITDYGFDTCGFDY
1ABC-123GFABC123-45-001
178975864TMBTumor Mutation BurdenNUMBER OF SEQUENCE VARIANTS497
497497
GRCh37.75Genetics Lab PlusDNAWHOLE EXOME SEQUENCING1SCREENING-12022-01-19-1
2ABC-123GFABC123-45-001ACME 500 GENE PANEL296757855TMBTumor Mutation BurdenNORMALIZED NUMBER OF SEQUENCE VARIANTS8.83/MBP8.838.83/MBPGRCh37.75ACME Genetics Inc.ctDNANEXT GENERATION TARGETED SEQUENCING1SCREENING-12022-01-19-1
3ABC-123GFABC123-45-001ACME 500 GENE PANEL396757855TMBTumor Mutation BurdenVARIANT SEQUENCE BURDEN INTERPRETATIONINTERMEDIATE
INTERMEDIATE

GRCh37.75ACME Genetics Inc.ctDNANEXT GENERATION TARGETED SEQUENCING1SCREENING-12022-01-19-1